Why the study?
Does acetylator phenotype predict the development of procainamide-induced SLE-like syndrome in patients treated for ventricular arrhythmias?
Population
28 patients with chronic ventricular arrhythmias
Comparison
Procainamide therapy guided by plasma monitoring vs Slow versus rapid acetylator phenotypes
Design
Cohort
Follow-up
one year
Authors
Loading...
Acetylator phenotype does not predict procainamide-induced SLE-like syndrome; leaves open whether antinuclear antibody monitoring identifies at-risk patients.
Does acetylator phenotype predict the development of procainamide-induced SLE-like syndrome in patients treated for ventricular arrhythmias?
Acetylator phenotype does not predict the development of procainamide-induced SLE-like syndrome when therapy is guided by plasma monitoring, though rapid appearance of antinuclear antibodies may indicate risk.
Sonnhag et al. (1979) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: